Azzad Asset Management Inc. ADV Purchases 62 Shares of Danaher Co. (NYSE:DHR)

Azzad Asset Management Inc. ADV increased its position in shares of Danaher Co. (NYSE:DHR) by 0.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,586 shares of the conglomerate’s stock after purchasing an additional 62 shares during the period. Azzad Asset Management Inc. ADV’s holdings in Danaher were worth $2,893,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of DHR. Wellington Management Group LLP increased its holdings in Danaher by 12.0% in the 4th quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock valued at $6,460,966,000 after acquiring an additional 2,998,161 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Danaher by 10.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock valued at $3,876,694,000 after acquiring an additional 1,619,586 shares during the last quarter. Capital International Investors increased its holdings in Danaher by 9.1% in the 4th quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock valued at $3,691,735,000 after acquiring an additional 1,334,781 shares during the last quarter. Norges Bank bought a new stake in Danaher in the 4th quarter valued at $1,752,382,000. Finally, Franklin Resources Inc. increased its holdings in Danaher by 6.4% in the 4th quarter. Franklin Resources Inc. now owns 6,620,170 shares of the conglomerate’s stock valued at $1,531,510,000 after acquiring an additional 395,498 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Insider Activity at Danaher

In related news, Director Alan G. Spoon sold 708 shares of Danaher stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the completion of the sale, the director now owns 116,202 shares in the company, valued at approximately $28,304,483.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, SVP Brian W. Ellis sold 4,000 shares of the business’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total value of $1,000,040.00. Following the completion of the sale, the senior vice president now owns 29,830 shares in the company, valued at approximately $7,457,798.30. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Alan G. Spoon sold 708 shares of the business’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the completion of the sale, the director now owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The disclosure for this sale can be found here. Insiders sold 148,783 shares of company stock worth $37,536,717 in the last 90 days. 10.90% of the stock is owned by corporate insiders.

Danaher Trading Down 0.1 %

Shares of DHR opened at $240.21 on Thursday. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $269.11. The company has a 50-day moving average of $255.88 and a 200 day moving average of $246.95. The firm has a market capitalization of $177.92 billion, a price-to-earnings ratio of 40.71, a PEG ratio of 3.82 and a beta of 0.84. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. During the same quarter last year, the business posted $2.36 EPS. The firm’s revenue for the quarter was down 2.6% on a year-over-year basis. On average, research analysts expect that Danaher Co. will post 7.63 EPS for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be issued a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, June 28th. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. Danaher’s payout ratio is 18.31%.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Robert W. Baird lifted their price target on shares of Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a report on Wednesday, April 24th. Evercore ISI dropped their price objective on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research note on Tuesday. Bank of America lifted their price objective on shares of Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 24th. Jefferies Financial Group assumed coverage on shares of Danaher in a research note on Monday, June 3rd. They issued a “buy” rating and a $295.00 price objective for the company. Finally, Barclays lifted their price objective on shares of Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 24th. Six analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and an average target price of $268.67.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.